[Click eStock] "SC Engineering's Bold Entry into the 53 Trillion Won Chinese Medical Beauty Market"

Valuefinder stated on the 29th that SCE Engineering is expected to see significant sales growth with its entry into the Chinese market through Sahwan Pharmaceutical and expansion into the global arena, warranting attention. No investment opinion or target price was provided.

SCE Engineering is a company specializing in EPC (Engineering, Procurement, and Construction) business and also operates a biocollagen business through its wholly owned subsidiary, Cellontech.

Researcher Lee Choongheon of Valuefinder said, “The EPC division is seeing increased orders due to expanded investments in the domestic petrochemical industry,” adding, “The subsidiary Cellontech is expected to achieve meaningful performance growth by entering the Chinese skin beauty injection market.”

Regarding the EPC division, Lee analyzed that profitability is expected to improve through expanded orders in advanced industries such as semiconductors and secondary batteries, beyond traditional industries. The scale of advanced industry projects in which SCE Engineering is participating in bids is estimated at 160 billion KRW, and the EPC division’s sales for this year are projected to be about 135 billion KRW.

Lee also said, “Cellontech is expected to see improved performance due to increased sales of Cartizol, which accounts for more than 50% of biocollagen sales,” and added, “Unlike existing treatments that only alleviated symptoms, Cartizol is understood to be increasing in demand due to its added tissue regeneration effects.”

He continued, “Cellontech’s biocollagen production volume has increased from 40kg to 80kg,” and added, “The total production capacity (Full CAPA), converted to sales, has increased by about 67%, from the previous 18 billion KRW to 30 billion KRW.”

In particular, Cellontech is accelerating its entry into the global medical beauty market. Researcher Lee judged that while the current Chinese filler market is saturated with hyaluronic acid (HA), polynucleotide (PN) has not yet entered the market, so the momentum for SCE Engineering’s entry into the Chinese market together with Sahwan Pharmaceutical is expected to be highlighted in the future.

This content was produced with the assistance of AI translation services.